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Muscle-eye-brain (MEB) disease is a congenital muscular dystrophy characterized by 
structural brain and eye defects. Here, we describe a 12-year-old boy with partial 
agenesis of corpus callosum, ventriculomegaly, flattened brainstem, diffuse pachygyria, 
blindness, profound cognitive deficiencies and generalized muscle weakness, yet 
without a clear dystrophic pattern on muscle biopsy. There was no glycosylation of α-
dystroglycan and the genetic screening revealed a novel truncating mutation, 
c.1545delC (p.Tyr516Thrfs*21), and a previously identified missense mutation, 
c.1469G>A (p.Cys490Tyr), in the protein O-mannose beta-1,2-N-
acetylglucosaminyltransferase 1 (POMGNT1) gene. These findings broaden the clinical 
spectrum of MEB to include pronounced hypotonia with severe brain and eye 
malformations, yet with mild histopathological changes in the muscle specimen, despite 
the absence of glycosylated α-dystroglycan. 
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Muscle-eye-brain disease (MEB, MIM 253280) belongs to a group of rare 
muscular dystrophies with autosomal recessive inheritance known as 
dystroglycanopathies.
1
 These diseases have a wide clinical spectrum, ranging from 
congenital muscular dystrophy (CMD) associated with severe brain and eye 
malformation [Walker Warburg syndrome (WWS, MIM 236670), MEB and Fukuyama 
congenital muscular dystrophy (FCMD, MIM 253800)]
2, 3
 to mild forms of muscle 
weakness with later onset and without brain involvement [Limb-girdle muscular 
dystrophy type 2O (LGMD2O, MIM 613157)].
4, 5
 MEB patients usually present muscle 
weakness and hypotonia at or soon after birth, and only some patients acquire 
independent ambulation. The most common cerebral and ocular features are 
pachygyria-type cortical neuronal migration disorder with hypoplasia of the brain stem 
and cerebellum, severe myopia, cataracts and retinal hypoplasia. Severe mental 
retardation and epilepsy are also constant clinical features.
1
 
It is known that aberrant O-glycosylation of α-dystroglycan (α-DG) underlies 
the pathogenesis of these diseases since the interaction between α-DG and extracellular 
matrix (ECM) proteins is mediated by O-linked glycans. This protein is the central 
component of the dystrophin-glycoprotein complex (DGC), and one of the best known 
O-mannosyl glycosylated proteins.
6
 There are two main O-mannosyl glycans on the 
mucin-like domain of α-DG that are critical for ligand binding activity. The first O-
mannosyl glycan of α-DG, Neu5Acα3Galβ4GlcNAcβ2Man-O-Ser/Thr, was described 
by Chiba et al for bovine peripheral nerve.
7
 Recently, a novel phosphorylated O-
mannosyl glycan required for laminin binding was identified on recombinant α-DG.
8
 
MEB is caused almost exclusively by mutations in the gene encoding the 
POMGNT1 glycosyltransferase (protein O-mannose beta-1,2-N-
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The clinical phenotype of MEB is heterogeneous, ranging from severe brain, eye 




Here we describe the clinical, histopathological and molecular genetic 
characterization of an unusual MEB patient with severe neurological and ocular 
abnormalities, yet with minimal myopathological changes. Immunohistological 
examination revealed a hypoglycosylated α-DG with a highly reduced laminin binding 
ability. The POMGNT1 gene of this patient suffered a novel frameshift mutation, giving 
rise to a truncated protein. These findings highlight the wide clinical spectrum of MEB 
and further emphasize the role of the POMGNT1 gene as the worldwide predominant 




A patient with muscle-eye-brain disease that was associated with abnormal α-
DG glycosylation, as witnessed in a muscle biopsy, was studied. 
 
Histological analysis and immunohistochemistry 
Two biopsies of the quadriceps muscle were performed (at 6 and 12 months of 
age) and analyzed by classical histology and immunohistochemistry. Ten µm-thick 
cryosections of muscle specimens from the patient and a control individual were stained 
with hematoxylin and eosin
11
 and mouse monoclonal antibodies against different glycan 
epitopes of α-DG (VIA4, Millipore Corporation, Billerica, MA, USA) and β-DG 
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(Novocastra, Newcastle-on-Tyne, UK) as described previously.
12
 Also, antibodies 
against dystrophin (DYS 1, 2 and 3), spectrin (both from Novocastra) and laminin-α2 
(MAB1922, Chemicon, Millipore Corporation) were used. 
 
Immunoblot analysis and laminin overlay assay 
Total protein extracts were obtained from frozen tissue samples and resolved by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (7% for α-DG 
and 10% for β-DG) following the procedures described previously.
13
 For laminin 
overlay assay the polyvinylidene difluoride (PVDF) membrane was blocked using a 
laminin binding buffer (LBB: 10mM triethanolamine, 140 mM NaCl, 1 mM MgCl2 and 
1 mM CaCl2, pH 7.6) containing 5% non-fat dry milk and incubated overnight with 
merosin (Sigma Aldrich, St Louis, MO, USA) at 4 ºC in LBB. The membrane was then 
washed and incubated with anti-laminin antibody (Sigma Aldrich) followed by 
horseradish peroxidase (HRP) conjugated anti-rabbit IgG (Santa Cruz Biotechnology 
Inc., Santa Cruz, CA, USA) and the bound proteins were visualized by 
chemiluminiscence (ECL Plus, GE Healthcare, UK). 
 
Mutation analysis 
Genomic DNA from the patient and his parents was isolated from total blood 
samples using standard techniques. The coding exons, flanking intronic regions and 
polyadenylation sites of the POMT1, POMT2, POMGNT1, FKTN, FKRP, LARGE and 
DAG1 genes were screened. A 5’-upstream region of approximately 650 bp (promoter 
region) was also screened for each gene. Polymerase chain reactions were performed 
using BIOTAQ
TM
 DNA Polymerase (Bioline, London, UK) and specific primers 
available under request. 
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This 12-year-old boy was the first child of non-consanguineous parents and there 
were no noteworthy features in his family medical history. An ultrasound scan in the 
third trimester revealed ventricular enlargement associated with midline anomalies, and 
a brain malformation was suspected. The child was born at term without any 
complications, weighing 2700 g and with an Apgar score of 8/9. From birth he 
exhibited marked axial and appendicular hypotonia with generalized muscle weakness 
and fixed knee flexion contractures, although no breathing or feeding difficulties were 
observed. He showed global hyporreflexia. The baby had poor visual alertness and 
abnormal eye movements. A neonatal ophthalmological examination revealed the 
persistence of the hyaloid artery and anomalous choroidal vascularization with retinal 
dysplasia. Biochemical evaluation demonstrated moderate elevation of serum creatine 
kinase (CK) levels (857 units/L: normal <175 units/L). The child had a normal 46, XY 
karyotype. Cranial magnetic resonance imaging (MRI) revealed partial absence of the 
corpus callosum, with ventriculomegaly and colpocepahly. There was also flattening of 
the brainstem and diffuse pachygyria predominantly affected the frontal lobes (Figure 
1A and B). 
In a follow-up examination the patient exhibited severe global developmental delay, and 
the axial and limb weakness persisted although the initial hypotonia gave rise to 
appendicular spasticity by age 3. The child’s ocular problems were exacerbated by 
bilateral glaucoma and cataracts. CK levels reached 3000 units/L. A new cranial MRI 
(at age 5) revealed periventricular white matter hyperintensities in T2 and fluid 
attenuated inversion recovery (FLAIR) sequences, in addition to the previous 
observations. At 7 years of age, the patient suffered a generalized tonic-clonic seizure 
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while sleeping. Conventional electroencephalography revealed background slowing, 
with slow waves in the temporo-occipital lobe of the left cerebral hemisphere. On 
examination at age 12, the patient was blind and suffered profound cognitive 
deficiencies, with no verbal language and he only reacted to tactile stimuli. He had 
spastic tetraplegia with hyperreflexia 3+ in the bilateral knees and Achilles tendon as 
well as fixed contractures with equinovarus foot. Moreover, he had not acquired 
unsupported sitting and his head control was incomplete. 
At that age the family declined to perform any further muscular studies. 
 
Histological analysis and immunohistochemistry 
Two biopsies of the quadriceps muscle were performed at 6 (Figure 1D) and 12 
months of age (Figure 1E) and analyzed by classical histology and 
immunohistochemistry. In both cases histological examination revealed mild myopathic 
changes with variation in fibre size and the presence of hyper-contracted fibers. The 
muscle architecture was preserved without endomysial fibrosis or fat tissue 
replacement. There were not necrotic or regenerating fibers. The diameter of the fibers 
varied generally between 10 and 50 microns. Muscle cryosections were stained for 
myofibrillar adenosine triphosphatase  (ATPase) at pH 4.3 (Figure 1G) showing a slight 
predominance of type II fibers and the atrophic fibers were mostly type II. There were 
no obvious intermediate stain type 2C fibers. 
However, when glycosylation state of α-DG was evaluated by 
immunohistochemistry, there was no staining in the muscle biopsy revealed with the 
VIA4 antibody (Figure 1I), whereas immunostaining with anti-β-DG antibody showed 
positive membrane staining (Figure 1K). Merosin, dystrophin and β-spectrin 
immunostaining was normal (data not shown). 
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Immunoblot analysis and laminin overlay assay 
The absence of functionally glycosylated α-DG was confirmed in immunoblots 
probed with the VIA4 antibody and this result was corroborated in a laminin overlay 
assay that revealed no detectable laminin binding (Figure 1L). 
 
Mutation analysis 
DNA sequencing revealed two heterozygous mutations in the POMGNT1 gene. 
One mutation was a novel 1-bp deletion in exon 18, c.1545delC (p.Tyr516Thrfs*21), 
which led to a frameshift and created a premature stop codon at amino acid 536 (Figure 
2A, right panel). This alteration was absent in 200 healthy control individuals. Sequence 
analysis of the corresponding exons in the parents’ POMGNT1 gene confirmed that this 
mutation was inherited from his father. The second mutation was a previously reported 
missense mutation located in exon 17, c.1496G>A (p.Cys490Tyr), which was carried by 
the patient’s mother (Figure 2A, left panel). 
 
Discussion 
The Spanish MEB patient described here presented a combination of severe 
ocular and cerebral malformations associated with marked hypotonia, muscle weakness 
and elevated serum CK levels but with almost normal muscle histology. 
From birth he exhibited hypotonia with generalized muscle weakness and severe 
global developmental delay. Functional capacity was limited as the patient was unable 
to acquire a sitting position or maintain head control unaided. These are common 
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Histological examination of the patient’s muscle revealed only mild myopathic 
changes and minimal variation in muscle fibre diameter, somewhat surprising given the 
pronounced phenotypic severity exhibited by the patient. Muscular dystrophy is present 
in all dystroglycanopathy patients, as reflected by biochemical parameters such as 
elevated serum CK levels and the appearance of necrosis, fibrosis and regenerative 
fibres in muscle biopsies.
15
 It has been described that in MEB dystrophic changes 
develop more slowly and become evident with increasing age. However, necrotic and 
regenerative fibers are a common feature at infancy (0-5 years), and architectural 
changes, such as fat infiltration become evident during later years.
16
 In contrast, our 
patient did not present necrotic and regenerating fibers at 1 year of age. It was not 
possible to monitor the progress of myopathological changes beyond 1 year of age since 
a muscle biopsy is invasive for the patient and a repetitive extraction is not always 
feasible. 
Also, mild dystrophic changes have been described in mild MEB patients with 
increased functional capacity that achieve independent ambulation.
14
 It is intriguing that 
despite severe brain and eye anomalies exhibited by the patient, only mild muscle 
histopathological alterations with absent glycosylated a-DG were found. 
The absence of the glycosylated form of α-DG was consistent with the 
correlation between the loss of α-DG glycosylation and the severity of the phenotype in 
patients carrying mutations in POMT1, POMT2 and POMGNT1.
17
 Our observations 
also confirm the correlation between the hypoglycosylation of α-DG and motor ability, 
whereby glycosylated α-DG is not detected in patients who never acquire an 
independent sitting position and there is stronger α-DG staining in individuals that 
achieve independent ambulation than in those who never walk.
18
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The patient carried a novel heterozygous mutation in the POMGNT1 gene, c.1545delC 
(p.Tyr516Thrfs*21), which generates a frameshift and an early stop codon and results in 
the deletion of 125 amino acids within the catalytic domain. The second mutation, 
c.1469G>A (p.Cys490Tyr), has been described previously in several 
dystroglycanopathy patients and in a few foetal cobblestone lissencephaly cases.
10, 19-21
 
The two mutations affect residues spanning the catalytic domain of POMGNT1 (Fig. 
2B). While the novel mutation p.Tyr516Thrfs*21 gives rise to a truncated protein, the 
Cys 490 residue, which according to the crystal structure of GnTI (N-
acetylglucosaminyltransferase I) forms a cysteine bridge with Cys
421
, is critical for the 
catalytic activity of POMGNT1. Indeed, the recent biochemical characterization of 
various POMGNT1 mutants containing Cys490Tyr mutation and nonsense mutations 
affecting residues within the catalytic domain such as Trp590X and Arg580X revealed 
no enzymatic activity, which allows postulating that the two alterations reported may 
strongly impair the enzyme activity.
22
 
We have characterized a severe dystroglycanopathy patient with brain and eye 
abnormalities typical of MEB but with very mild histological muscular changes. Severe 
muscle weakness, hypotonia and elevated serum CK levels were detected, along with 
the absence of glycosylated α-DG. Our findings broaden the clinical spectrum of MEB 
and suggest that analysis of POMGNT1 gene mutations may be useful in patients with 
severe structural brain and ocular defects, mental retardation and congenital hypotonia, 
independent of the severity of the dystrophic pattern in skeletal muscle. Given the 
overlapping clinical spectra of dystroglycanopathy patients, further understanding of the 
different phenotypes of MEB and other dystroglycanopathies will aid the establishment 
of gene priority in genetic analysis of these patients. 
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Figure 1. Brain magnetic resonance imaging and muscle biopsy analysis. (A) Sagittal 
T1-weighted image showing ventricular enlargement [1] and partial absence of the 
corpus callosum [2]. The pons is thinned with a concave posterior border [3]. (B) Axial 
FLAIR-weighted image showing ventriculomegaly [1], pachygyric changes in frontal 
cortex [4] and periventricular white matter hyperintensities. (C, D and E) Hematoxylin 
and eosin staining of patient’s muscle at 6 months (D) and 12 months of age (E) 
showing mild variation in fibre size compared to a muscle sample from a healthy 
control infant (C) of around one year of age. (F and G) Histological staining for ATPase 
at pH 4.3 indicates the presence of type II atrophic fibers and no intermediate stain type 
2C fibers were noted. (H and I) Immunostaining for α-dystroglycan of skeletal muscle 
from the patient and from an adult healthy individual, using an antibody against the 
glycosylated epitope (VIA4 antibody). (J and K) Immunostaining for β-dystroglycan. 
Objectives: 40X (C, D, E, F, G, I and K) and 20X (H and J). (L) Western blot and 
laminin overlay reveal the absence of glycosylated α-dystroglycan in the MEB patient 
using the VIA4 antibody and they demonstrate a complete inability to bind laminin. A 
band at around 200 kDa representing the endogenous laminin was detected in both 
control and patient lanes. The samples were analyzed for β-dystroglycan, which also 
served as a loading control. 
 
Figure 2. (A) Mutation analysis of the POMGNT1 gene confirmed that this patient was 
heterozygous for the missense mutation p.Cys490Tyr in exon 17 (left upper panel), and 
the truncating mutation p.Tyr516Thrfs*21 in exon 18 (right upper panel). His father 
was heterozygous for the mutation p.Tyr516Thrfs*21 mutation (right middle panel) and 
his mother heterozygous for the p.Cys490Tyr mutation (left bottom panel). Nucleotide 
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changes are indicated by asterisks (*). (B) Scheme of the POMGNT1 protein indicating 
the mutations found in the patient (in bold and red) together with all the other mutations 
reported to date in association with the mutation p.Cys490Tyr. The interrupted line 
connects heterozygous mutations, while an asterisk (*) indicates the homozygous forms. 
The cytoplasmic domain is shown in green, the transmembrane domain in black, the 
stem domain in blue, and in violet the catalytic domain, divided into the UDP-
GlcNAc/Mn
+2
 binding region (300 to 530 amino acids) and the substrate specific region 
(531 to 660 amino acids). 
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